Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (261-270 of 471) with videos related to

Pageof 48
Sort By:
Ejhaem|July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myelomaPaul G Richardson, Sundar Jagannath, Ajai Chari, et al.
American Journal of Hematology|February 4, 2016
Clinical characteristics and outcomes in biclonal gammopathiesTrey C Mullikin, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|November 23, 2013
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapyTaxiarchis V Kourelis, Shaji K Kumar, Geetika Srivastava, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.
Blood|May 24, 2013
Outcomes of patients with POEMS syndrome treated initially with radiationMichael S Humeniuk, Morie A Gertz, Martha Q Lacy, et al.
American Journal of Hematology|February 19, 2019
Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosisM Hasib Sidiqi, Surendra Dasari, Ellen D McPhail, et al.
Leukemia|December 9, 2022
Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
Pageof 48

Showing results (261-270 of 471) with videos related to

Sort By:
Pageof 48
Ejhaem|July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myelomaPaul G Richardson, Sundar Jagannath, Ajai Chari, et al.
American Journal of Hematology|February 4, 2016
Clinical characteristics and outcomes in biclonal gammopathiesTrey C Mullikin, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|November 23, 2013
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapyTaxiarchis V Kourelis, Shaji K Kumar, Geetika Srivastava, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.
Blood|May 24, 2013
Outcomes of patients with POEMS syndrome treated initially with radiationMichael S Humeniuk, Morie A Gertz, Martha Q Lacy, et al.
American Journal of Hematology|February 19, 2019
Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosisM Hasib Sidiqi, Surendra Dasari, Ellen D McPhail, et al.
Leukemia|December 9, 2022
Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
Pageof 48